Carlyle Group acquired a minority stake in Ambio, a fast-growing global peptide active pharmaceutical ingredient contract development and manufacturing organization, from MVM Partners, a British private equity firm. MVM retains a significant interest in Ambio. Financial terms were not disclosed. Ling Yang, a Managing Director of the Carlyle Asia Partners advisory team, said, “Carlyle sees strong growth potential in the peptide API CDMO business, as well as great opportunities in the generic peptide business. Ambio is well positioned to capture these significant growth opportunities by capitalizing on its demonstrated strong technical capabilities and high quality. Its business model offers customer nimbleness and cost advantage. We look forward to leveraging Carlyle’s healthcare network and capital markets knowhow globally and in China to help Ambio in its next phase of growth.”